BioCentury
ARTICLE | Clinical News

EPT1647: Phase I/II started

October 31, 2005 8:00 AM UTC

EPT began a dose-escalation, single-blind, 20-week, U.K. Phase I/II trial in up to 30 healthy volunteers to determine the maximum tolerated dose (MTD) of topical EPT1647. The topical formulation is de...